Abstract

Der 30. Manfred Donike Workshop für Dopinganalyse fand vom 26. Februar bis 02. März 2012 in Köln statt. Der im selben Jahr veröffentlichte Kongressband enthält die folgenden Beiträge: 1. V.F. Sardela, K. Deventer, H.M.G. Pereira, F.R. de Aquino Neto, P.van Eenoo: Development and validation of a UHPLC-tandem mass spectrometric method for the direct detection of formoterol in human urine; 2. A.-K. Orlovius, S. Guddat, M.K. Parr, M. Guetschow, M. Thevis, W. Schänzer: In vitro formation of fenoterol sulfates using different tissue preparations and recombinant sulfiotransferases; 3. G. Muñoz, E. Tudela, J.A. Muñoz-Guerra: Matrix effects marker for multianalyte analysis of glucocorticoids and diuretics by LC-MS/MS in biological samples; 4. M. Mazzarino, I. Fiacco, A. Palermo, X. de la Torre, F. Botrè: The use of cytochrome P450 inhibitors in sport. A new generation of doping masking agents?; 5. N. Jan, F. Marclay, N. Schmutz, M. Smith, A. Lacoste, M. Saugy: Use of forensic investigations in Anti-Doping; 6. M.K. Parr, J. Daniels, N.E. Schlörer, W. Schänzer: Structure proof of tibolone 3-hydroxy metabolite; 7. T. Sobolevsky, G. Rodchenkov: Long-term detection of dehydrochloromethyltestosterone: one-year experience; 8. M. Okano, T. Ueda, H. Kano, Y. Nishitani, A. Ikekita, M. Sato, S. Kageyama: UDP-glucuronosyltransferase 2B17 qenotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse by female athletes; 9. T. Sobolevsky, G. Rodchenkov: Oxymetholone and desoxymethyltestosterone: how many metabolites do we know? HPLC clean-up to identify the new targets; 10. F. Badoud, E. Grata, J. Boccard, S. Rudaz, J.-L. Veuthey, M. Saugy: Profiling of endogenous steroids by UHPLC-QTOF-MSE; 11. M.K. Parr, W. Schänzer, N. Schlörer, E. Voronina, J. Hengevoss, P. Diel: Alternative detection strategies for anabolic steroid abuse by NMR metabonomics and endocrine feedback loop analyses; 12. P. van Renterghem, P.-E. Sottas, M. Saugy, P. van Eenoo: Validation of a steroidomic model and its application in doping control; 13. L. Lootens, L. Geldoft, L. Decroix, K. Deventer, F. Botrè, G. Leroux-Roels, P. Meuleman, P. van Eenoo: Metabolic study of Prostanozol using human liver microsomes and humanized mice; 14. C. Gómez, O. Pozo, J. Marcos, J. Segura, R. Ventura: Alternative long-term markers for the detection of methyltestosterone misuse; 15. H.M.G. Pereira, A. Campos de Azevedo Silva, S. Soares Barbosa, R. Salles Ferreira Silva, M. Costa Padilha, F.R. Aquino Neto: Two-dimensional comprehensive gas chromatography coupled to time of flight mass spectrometry in doping control: evaluation of the chromatographic plane organization; 16. N. de Brabanter, W. van Gansbeke, L. Geldof, P. van Eenoo: Improvements in GC-QqQ-MS screening, 1 year of experience; 17. K. Deventer, A. Jimenez, S. Esposito, K. Roels, Kris, P. van Eenoo: Application of UHPLC-orbitrap based mass spectrometry with scan-to-scan polarity switching for the direct detection of doping agents in urine; 18. M. Polet, W. van Gansbeke, K. Deventer, P. Van Eenoo: Development of a sensitive GC-C-IRMS method for the analysis of androgens; 19. A. Ouellet, N. LeBerre, C. Ayotte: A simplified and accurate method for the analysis of urinary metabolites of testosterone-related steroids using gas chromatography-combustion-isotope ratio mass spectrometry; 20. S. Esposito, K. Deventer, P. van Eenoo: Doping control analysis of desmopressin in human plasma and urine by HPLC-ESI-MS/MS; 21. Y. Dehnes, M. Drange, S.B. Ottersen, P. Hemmersbach: Longitudinal profiles of indirect markers for GH misuse; 22. I. Möller, A. Thomas, H. Geyer, W. Schänzer, M. Thevis: Detection and method validation of peginesatide in human serum by means of LC-MS/MS; 23. E. Machala, J. Grainger, V. Agon, C. Goebel: Validation and implementation of MAIIA columns into routine analysis of urinary EPO screening; 24. P. Desharnais, J.-F. Naud, C. Ayotte: Desialylation improves the detection of recombinant erythropoietins in urine samples analyzed by SDS-PAGE; 25. M. Okano, Y. Nishitani, M. Sato, S. Kageyama: Administration study of growth factors; 26. S. Esposito, K. Deventer, P. van Eenoo: Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products; 27. E. Virus, M. Dikunets, I. Sukhanova, T. Sobolevsky, G. Rodchenkov: High-temperature liquid chromatography/orbitrap mass spectrometry with hypercarb column for selective screening of exogenous anabolic steroids in human urine; 28. T. Sobolevsky, M. Dikunets, I. Sukhanova, G. Rodchenkov: Applicability of routine analytical procedures to detect andarine and ostarine. A comparative study; 29. T. Sobolevsky, N. Savelieva, E. Semenistaya, G. Rodchenkov: Importance of phase II metabolites for the detection of beta-blockers by direct urine analysis; 30. A. Bourmpopoulou, M. Roumana, F. Vassilaki, Y.S. Angelis, M. Lyris, M. Tsivou, P. Kiousi, A. Vouroudi, M.A. Koupparis, C. Georgakopoulos: A unified doping screening procedure based on LLE with ethyl acetate and combined GCMS, GCHRMS and LCQTOFMS analysis; 31. J. Grainger, G. Trout, C. Goebel: Multi-residue extraction and analysis method for prohibited substances in urine; 32. O. Krug, A. Thomas, K. Walpurgis, G. Sigmund, W. Schänzer, M. Thevis: Analysis of confiscated products with suspiciously doping relevant ingredients by GC-MS, LC-HRMS and LC-MSn; 33. N. de Brabanter, W. van Gansheke, F. Hooghe, P. van Eenoo: Fast quantification of 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THCA) using microwave-accelerated derivatisation and gas chromatography-triple quadrupole mass spectrometry (GC-QqQ-MS); 34. M. Mazzarino, I. Fiacco, S. Turi, F. Botrè: A simple and rapid procedure for the determination of the urinary concentration of formoterol by LC-MS/MS; 35. G. Ergaliuly, K. Balmukanov, G. Beksultanova, A. Shaldybayeva, T. Talbayev: Detection and confirmation of hydroxyethylstarch (HES) in human urine by liquid chromatography-mass spectrometry; 36. F. Oueslati, R. Slouma, N. Halabi, F. Safta, M.H. Loueslati: Detection of bendroflumethiazide metabolites in human urine using liquid chromatography-tandem mass spectrometry: application to urinary excretion study; 37. M. Okano, T. Osada, M. Sato, A. Uchiyama, S. Kageyama: Mass spectrometric identification of epitiostanol metabolite: in vitro metabolism using human embryonic stem cell (hESC)-derived hepatocytes and in vivo excretion study in human; 38. T. Sobolevsky, M. Dikunets, I. Sukhanova, E. Virus, G. Rodchenkov: Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine; 39. T. Sobolevsky, I. Prasolov, M. Dikunets, G. Rodchenkov: In vitro metabolic studies of AM2233 and JWH-210, novel synthetic cannabinoids; 40. T. Sobolevsky, I. Prasolov, G. Rodchenkov: Detection of urinary metabolites of AM-2201 and UR-144, novel synthetic cannabinoids; 41. I. Fiacco, X. de la Torre, F. Donati, M. Mazzarino, F. Botrè: Salbutamol metabolism. How to differentiate oral vs. inhaled administrations: looking outside the box; 42. C. Gómez, A. Fabregat, O. Pozo, J. Marcos, K. Deventer, J. Segura, R. Ventura: Exploring boldione metabolism b LC-MS/MS; 43. J. Lu, G. He, X. Wang, Y. Xu, Y. Wu, Y. Dong, Z. He, X. Liu, T. Bo, G. Ouyang: Detection of new clomiphene metabolites in human urine by liquid chromatography - quadrupole time-of-flight tandem mass spectrometry; 44. M. Vahermo, H. Sutinen, A. Leinonen, J. Yli-Kauhaluoma: Synthesis and characterization of the O-desisopropyl metabolite of bisoprolol; 45. P. van Renterghem, P.-E. Sottas, M. Saugy, F. Delbeke, L. Brooker, M. Polet, W. van Thuyne, H. Geyer, W. van Gansbeke, W. Schänzer, P. van Eenoo: Summary of the Alternative Steroid Profiling WADA project; 46. D. Jardines, D. Curcio, X. de la Torre, C. Colamonici, M.G. Abate, F. Molaioni, F. Botrè: Longitudinal studies in steroid profiling - a multivariate approach: IRMS extension; 47. D. Jardines, X. de la Torre, F. Botrè: Hydroxylated steroids stability; 48. U. Mareck, G. Fußhöller, H. Geyer, G. Opfermann, M. Thevis, W. Schänzer: GC -single and -triple quadrupole mass spectrometry in steroid profiling; 49. I.R. Hullstein, T.S. Selmer, C. Sagredo, J. Henninge, A. Juul, P. Hemmersbach: Urinary steroid profiles after use of testosterone by different routes of administration - how do we detect doping with low doses?; 50. D. Müller, G. Opfermann, S. Rojas, N. Schlörer, A. Pokrywka, D. Kwiatkowska, P. Diel, W. Schänzer, M.K. Parr: 5α-Androst-1-ene-3,17-dione: metabolism, influence on steroid profile and biological activity; 51. T. Piper, C. Emery, M. Saugy: Norandrosterone analysis by GC/C/IRMS; 52. L. Brooker, J. Drury, N. Hasick, A. Idan, D. Handelsman, C. Goebel: Co-administration of dietary supplements containing dehydroepiandrosterone and pregnenolone: investigation of the impact on routine GC-C-IRMS doping control results; 53. T. Piper, C. Emery, M. Saugy: Improved sample preparation and subsequent investigations on population based thresholds for carbon isotope ratios of urinary steroids; 54 V. Pop, M. Zorio, A. Pop, I. Vajiala: Population study on ∆δ13C values of endogenous steroids in Romania; 55. S. Jain, T. Kaur, T. Garg, A. Srivastava, A. Soni, A. Beotra: Effect of storage condition on 13C/12C ratios and steroid profile; 56. O. Haupt, S. Tchoukouegno Ngueu, P. Diel, M.K. Parr: Anabolic effect of ecdysterone results in hypertrophy of C2C12 myotubes by an estrogen receptor mediated pathway; 57. C. Covelli, X. de la Torre, F. Botrè: Tramadol detection in sports; 58. A. Coetzee, L.J. Holtzhauzen, P. van der Merwe: Prevalence of the use of analgesics and non-steroidal anti-inflammatory drugs in urine of South African athletes; 59. A. Beotra, S. Ahi, S. Jain: Monitoring of glucocorticosteroids in out-of-competition testing to study the potential pattern of misuse; 60. S. Ahi, A. Beotra, A. Upadhyay, N Jain, R. Singh, S. Jain: Excretion profile of inhaled formoterol: distinguishing between therapeutic use and abuse in sports; 61. T. Kaur, S. Dubey, S.P. Singh, S. Jain, J. Agrawal, M. Chakraborty, A. Beotra: Monitoring of nicotine use in sport; 62. A. Reinartz, G. Sigmund, M. Machnik, M. Thevis, W. Schänzer: Prevalence of antidepressants and biosimilars in elite sport - a follow-up study; 63. K. Koehler, H. Braun, M. Thevis, W. Schänzer: Glycerol as prohibited substance: meta-analysis on the effects of glycerol administration on haemoglobin, haematocrit and plasma volume; 64. F. Donati, P. Placidi, M. Abagnale, X. De La Torre, F. Botrè: Flow cytometry on the move. Extending feasibility of the Cytomics FC500: from homologous blood transfusion detection to soluble molecules multiassay; 65. A. Krumbholz, P. Anielski, N. Reisch, D. Thieme: Hair analyses of steroids as tool of disease control in patients with congenital adrenal hyperplasia; 66. S. Jain, R. Lal, A. Raj, D. Tyagi, A. Beotra, T. Kaur: Characteristics of IEF Patterns and SDS-PAGE Result of Indian EPO biosimilars. AGa und Inhaltsverzeichnis